Compare Stocks: AMRN, PCRX, IVA, and AMPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.78	$20.84	$16.65 ▼ $29.52	$1.01B	0.92	379,230 shs	410,947 shs
AMRN Amarin	$13.80	$14.17	$12.96 ▼ $20.90	$291.46M	0.76	83,048 shs	49,369 shs
IVA Inventiva	$4.02	$4.58	$3.35 ▼ $7.98	$834.99M	0.71	889,085 shs	1.71 million shs
PCRX Pacira BioSciences	$25.36	$25.48	$18.80 ▼ $27.66	$1.01B	0.26	473,133 shs	538,038 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+2.59%	+13.73%	+20.65%	-15.25%
AMRN Amarin	0.00%	+1.25%	-1.92%	-10.10%	-8.06%
IVA Inventiva	0.00%	-15.90%	-12.61%	+6.91%	-28.34%
PCRX Pacira BioSciences	0.00%	-3.76%	+10.26%	+11.52%	-6.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.78	$20.84	$16.65 ▼ $29.52	$1.01B	0.92	379,230 shs	410,947 shs
AMRN Amarin	$13.80	$14.17	$12.96 ▼ $20.90	$291.46M	0.76	83,048 shs	49,369 shs
IVA Inventiva	$4.02	$4.58	$3.35 ▼ $7.98	$834.99M	0.71	889,085 shs	1.71 million shs
PCRX Pacira BioSciences	$25.36	$25.48	$18.80 ▼ $27.66	$1.01B	0.26	473,133 shs	538,038 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+2.59%	+13.73%	+20.65%	-15.25%
AMRN Amarin	0.00%	+1.25%	-1.92%	-10.10%	-8.06%
IVA Inventiva	0.00%	-15.90%	-12.61%	+6.91%	-28.34%
PCRX Pacira BioSciences	0.00%	-3.76%	+10.26%	+11.52%	-6.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-5.38% Downside
AMRN Amarin	1.33	Sell	$13.00	-5.80% Downside
IVA Inventiva	3.10	Buy	$15.38	282.46% Upside
PCRX Pacira BioSciences	2.38	Hold	$29.83	17.64% Upside

Current Analyst Ratings Breakdown

Latest AMRN, PCRX, IVA, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	PCRX Pacira BioSciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$28.00
9/1/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/17/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$21.00 ➝ $20.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$19.00 ➝ $20.00
8/5/2026	PCRX Pacira BioSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$24.00 ➝ $25.00
8/5/2026	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.41	$4.25 per share	5.59	$17.17 per share	1.38
AMRN Amarin	$213.65M	1.36	$0.36 per share	38.23	$22.07 per share	0.63
IVA Inventiva	$5.07M	164.69	N/A	N/A	($0.22) per share	-18.27
PCRX Pacira BioSciences	$726.41M	1.39	$3.86 per share	6.57	$16.11 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	14.07	9.18	4.58	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)
PCRX Pacira BioSciences	$7.03M	$0.35	72.46	10.57	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)

Latest AMRN, PCRX, IVA, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2026	Q2 2026	IVA Inventiva	-$0.20	N/A	N/A	N/A	$6.35 million	N/A
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
AMRN Amarin	N/A	3.67	2.67
IVA Inventiva	N/A	3.16	3.16
PCRX Pacira BioSciences	0.54	5.04	3.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
AMRN Amarin	22.25%
IVA Inventiva	19.06%
PCRX Pacira BioSciences	99.73%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
AMRN Amarin	4.21%
IVA Inventiva	32.00%
PCRX Pacira BioSciences	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
AMRN Amarin	360	21.12 million	20.23 million	Optionable
IVA Inventiva	73	207.71 million	141.24 million	Not Optionable
PCRX Pacira BioSciences	829	39.86 million	37.31 million	Optionable

AMRN, PCRX, IVA, and AMPH Headlines

Recent News About These Companies

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages

September 11 at 4:28 AM | marketbeat.com

Leerink Partners Initiates Coverage on Pacira BioSciences (NASDAQ:PCRX)

September 11 at 1:54 AM | americanbankingnews.com

Leerink Partners initiates coverage of Pacira BioSciences at market perform

September 10, 2026 | msn.com

Pacira BioSciences (NASDAQ:PCRX) Now Covered by Leerink Partners

September 9, 2026 | marketbeat.com

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2026 | globenewswire.com

Public Employees Retirement System of Ohio Purchases New Position in Pacira BioSciences, Inc. $PCRX

September 9, 2026 | marketbeat.com

Wellington Management Group LLP Has $14.29 Million Holdings in Pacira BioSciences, Inc. $PCRX

September 8, 2026 | marketbeat.com

Legal & General Group Plc Buys Shares of 88,640 Pacira BioSciences, Inc. $PCRX

September 6, 2026 | marketbeat.com

296,880 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Bank of New York Mellon Corp

September 4, 2026 | marketbeat.com

Man Group plc Buys New Holdings in Pacira BioSciences, Inc. $PCRX

September 1, 2026 | marketbeat.com

200,073 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Empowered Funds LLC

September 1, 2026 | marketbeat.com

PDT Partners LLC Makes New Investment in Pacira BioSciences, Inc. $PCRX

August 27, 2026 | marketbeat.com

Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX

August 20, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares

August 19, 2026 | insidertrades.com

Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX

August 19, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock

August 18, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial

August 17, 2026 | marketbeat.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages

August 17, 2026 | marketbeat.com

Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX

August 17, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Lowered to "Buy" Rating by Wall Street Zen

August 16, 2026 | marketbeat.com

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?

August 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMRN, PCRX, IVA, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.78 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$24.08 +0.30 (+1.26%)

As of 09/11/2026 07:30 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Amarin NASDAQ:AMRN

$13.80 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$13.81 +0.01 (+0.07%)

As of 09/11/2026 07:30 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inventiva NASDAQ:IVA

$4.02 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.05 +0.03 (+0.85%)

As of 09/11/2026 07:55 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Pacira BioSciences NASDAQ:PCRX

$25.36 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$25.36 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN, PCRX, IVA, and AMPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN, PCRX, IVA, and AMPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN, PCRX, IVA, and AMPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMRN, PCRX, IVA, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Amarin NASDAQ:AMRN

Inventiva NASDAQ:IVA

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN, PCRX, IVA, and AMPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN, PCRX, IVA, and AMPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN, PCRX, IVA, and AMPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMRN, PCRX, IVA, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Amarin NASDAQ:AMRN

Inventiva NASDAQ:IVA

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools